ImmuPharma (LSE:IMM) is pushing to turn its lead drug candidate, P140, into a commercial partnership before the end of 2026. Its half-year report, published on 15 September 2026, showed a narrower operating loss and slightly more cash than a year earlier, but a sharp increase in the headline loss linked to its equity funding arrangement, and the shares fell on the day of the results.
What the company does
ImmuPharma is a UK-listed drug discovery and development company. Its lead asset, P140, is a peptide being explored as a treatment for autoimmune and inflammatory conditions, including lupus, and the company has US licensing partner Avion Pharmaceuticals for the programme. It is also developing Kapiglucagon, a glucagon product, and has early-stage anti-infective programmes called BioAMB, targeting fungal infections, and BioCIN, aimed at bacterial infections.
Latest developments
The interim report said ImmuPharma received a first UK patent examination report for P140 in March 2026, and filed an international PCT application after the period end. Post-period research reported activity for P140 in a preclinical model of MASH, a form of fatty liver disease, and the company highlighted separate research by the University of Murcia. On 15 September it also announced a new peer-reviewed publication. Management said Avion remains supportive and that it is aiming for a value-enhancing commercial deal for P140 in 2026, although no agreement has yet been announced.
Kapiglucagon has moved from planning into development work. The company launched an IND-enabling programme in May 2026, appointed Bachem for the active pharmaceutical ingredient in June, selected Thermo Fisher as a contract development and manufacturing partner in July, and named a bioanalytical contract research partner in August. Planned discussions with the US Food and Drug Administration are expected to shape the path towards an IND submission and first-in-human studies.
Financial picture
For the six months to 30 June 2026, the operating loss narrowed to £1.07 million from £1.23 million, while research and development spending fell to £0.59 million. The total loss rose to £4.70 million, mainly because of a £3.36 million finance loss from remeasuring the derivative asset linked to its Lanstead sharing agreement. Cash at 30 June stood at £0.70 million, compared with £0.40 million a year earlier.
In March and April 2026 the company raised gross proceeds of about £6.47 million, made up of a £6.0 million subscription by Lanstead and around £0.47 million from a retail offer. Under the sharing agreement, the eventual cash received depends on ImmuPharma's share price relative to a benchmark over 20 months. The company says this funding provides a runway into at least the second half of 2028. Shares in issue rose to 625.3 million. ImmuPharma does not pay a dividend.
Sector and index context
ImmuPharma is one of many early-stage biotechnology companies on the FTSE AIM All Share Index, a segment where valuations often move sharply on clinical, regulatory and partnering news. The company has a difficult history with P140, which previously failed to meet its primary endpoint in a Phase III lupus trial, and its current strategy relies on new data and partners to rebuild the programme.
Key risks
The main risks are failure to secure a P140 licensing deal, setbacks in regulatory discussions for Kapiglucagon, and the uncertain value of the Lanstead arrangement, which falls if the share price weakens. All of its programmes remain at preclinical or development stage, so commercial revenue is some way off, and further dilution cannot be ruled out.
What to watch next
Investors will look for news of a P140 commercial agreement, which management has targeted for 2026, along with the outcome of FDA interactions on Kapiglucagon and progress on patent filings.






Please wait processing your request...